sterna biologicals GmbH & Co. KG
STERNA BIOLOGICALS TO PARTICIPATE IN UPCOMING INTERNATIONAL CONFERENCES IN H1 2018
DGAP-News: sterna biologicals GmbH & Co. KG / Key word(s): Conference STERNA BIOLOGICALS TO PARTICIPATE IN UPCOMING INTERNATIONAL CONFERENCES IN H1 2018 Marburg, Germany, 01 February 2018 – sterna biologicals GmbH & Co. KG (sterna), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today announces its participation in the following key scientific and partnering conferences in the first half of 2018:
As further details on the conferences and presentations are available, this information will be updated on the Company’s website: http://www.sterna-biologicals.com/. Parties interested in meeting the sterna representatives at one of these conferences, please contact Derya Akar at derya.akar@sterna-biologicals.com. ABOUT STERNA BIOLOGICALS Sterna biologicals GmbH & Co. KG is an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and ulcerative colitis. By targeting transcription factors that play a pivotal role in regulating Th1 and Th2 inflammatory mechanisms, the Company’s proprietary DNAzyme-based drug candidates can intervene with upstream inflammatory processes and address related diseases more effectively. Sterna has currently four programs in Phase II development. For more information, please visit www.sterna-biologicals.com.
Christian Pangratz sterna biologicals GmbH & Co. KG
Anne Hennecke
01.02.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |